Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927770 | 0.82 | BACE1 (0.42) | TRPA1ALDH1A1KDM4EKMT2AKRAS | |
| SCHEMBL29464941 | 0.82 | BACE1 (0.42) | TRPA1ALDH1A1KDM4EKMT2AKRAS | |
| SCHEMBL2737349 | 0.72 | RPS6KA3 (0.42) | RPS6KA3TRPA1SLC22A12ALDH1A1LIMK1 | |
| SCHEMBL1225544 | 0.71 | ADORA2B (0.49) | ADORA2BALDH1A1KDM4EKMT2ABACE1 | |
| SCHEMBL24910290 | 0.69 | RPS6KA3 (0.46) | RPS6KA3TRPA1SLC22A12LIMK1CYP17A1 | |
| SCHEMBL12029013 | 0.69 | RPS6KA3 (0.39) | RPS6KA3TRPA1SLC22A12ALDH1A1S1PR1 | |
| SCHEMBL29435625 | 0.69 | RPS6KA3 (0.39) | RPS6KA3TRPA1SLC22A12ALDH1A1S1PR1 | |
| SCHEMBL19968786 | 0.68 | BACE1 (0.44) | TRPA1ALDH1A1KDM4EKMT2AKRAS | |
| SCHEMBL21733739 | 0.68 | KDM4E (0.41) | ALDH1A1KDM4EKMT2ABACE1 | |
| SCHEMBL22117225 | 0.67 | BACE1 (0.40) | ADORA2BALDH1A1KDM4EKMT2AKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | RPS6KA3 3471/4885TRPA1 97/4885SLC22A12 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.